2,003 results match your criteria: "National institute of oncology[Affiliation]"
ESMO Open
January 2025
Abramson Cancer Center, University of Pennsylvania, Philadelphia, USA.
Background: Concomitant intake of proton pump inhibitors (PPIs) may create drug-drug interactions, potentially impacting efficacy of anticancer agents. In the phase III PALLAS trial, the addition of palbociclib capsules to standard adjuvant endocrine therapy in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer did not improve invasive disease-free survival (iDFS). We explored whether concomitant use of PPIs affected survival outcomes in patients treated with palbociclib in PALLAS.
View Article and Find Full Text PDFCancer Immunol Immunother
January 2025
Oncology Unit, Macerata Hospital, Macerata, Italy.
Introduction: Renal cell carcinoma (RCC) is one of the most common types of urogenital cancer. The introduction of immune-based combinations, including dual immune-checkpoint inhibitors (ICI) or ICI plus tyrosine kinase inhibitors (TKIs), has radically changed the treatment landscape for metastatic RCC, showing varying efficacy across different prognostic groups based on the International Metastatic RCC Database Consortium (IMDC) criteria.
Materials And Methods: This retrospective multicenter study, part of the ARON-1 project, aimed to evaluate the outcomes of favorable-risk metastatic RCC patients treated with immune-based combinations or sunitinib.
Cureus
November 2024
Hematology, Cheikh Khalifa International University Hospital, Mohammed VI University of Sciences and Health, Casablanca, MAR.
Evans syndrome (ES) is a rare syndrome characterised by the association of autoimmune idiopathic hemolytic anemia (AIHA) with immune thrombocytopenia (ITP) and, less commonly, autoimmune neutropenia (AIN). ES may be primary or secondary to some aetiology, including, exceptionally, tuberculosis. We describe a case of association between pulmonary and medullary tuberculosis and Evans syndrome with an effective response to antitubercular treatment and corticosteroids.
View Article and Find Full Text PDFRadiol Case Rep
February 2025
Department of Radiology, National Institute of Oncology, CHU Ibn Sina, Faculty of Medicine and Pharmacy of Rabat, Rabat, Morocco.
Pleomorphic adenoma (PA) is the most common benign histological form of salivary gland tumors, particularly in the parotid gland, primarily affecting women between the ages of 40 and 60. However, its occurrence in the trachea is very rare. This article reports the case of a 48-year-old woman presenting with progressive dyspnea and weight loss, initially suspected of having a pulmonary embolism.
View Article and Find Full Text PDFJCO Glob Oncol
December 2024
Early Drug Development for Innovative Therapies Division, European Institute of Oncology, IRCCS, Milan, Italy.
Purpose: Trimodal therapy (TMT) is the standard treatment for patients with nonmetastatic inflammatory breast cancer (IBC). TMT consists of neoadjuvant systemic therapy, modified radical mastectomy (MRM), and postmastectomy radiation therapy. Although broadly considered the best approach for IBC, in the United States, only a third of patients receive TMT.
View Article and Find Full Text PDFPathol Oncol Res
December 2024
Department of Pathology, Forensic and Insurance Medicine, Semmelweis University, Budapest, Hungary.
Pancreatic adenocarcinoma is one of the deadliest forms of cancer with no effective therapeutic options. A KRAS mutation can be found in up to 90% of all pancreatic tumors, making it a promising therapeutic target. The introduction of new KRAS inhibitors has been a milestone in the history of KRAS mutant tumors; however, therapeutic resistance limits their efficacy.
View Article and Find Full Text PDFInt J Mol Sci
November 2024
Department of Molecular Genetics and The National Tumour Biology Laboratory, National Institute of Oncology, Comprehensive Cancer Centre, Ráth György u. 7-9, 1122 Budapest, Hungary.
Using multigene panel testing for the diagnostic evaluation of patients with hereditary breast and ovarian cancer (HBOC) syndrome often identifies clinically actionable variants in genes with varying levels of penetrance. High-penetrance genes (, , , , , , ) inform specific clinical surveillance and therapeutic decisions, while recommendations for moderate-penetrance genes (, , , , , , , , , , , ) are more limited. A detailed disease history, including pedigree data, helps formulate the most appropriate and personalised management strategies.
View Article and Find Full Text PDFJ Craniofac Surg
December 2024
I Department of Oncological and Reconstructive Surgery, National Institute of Oncology, Gliwice, Poland.
Eur J Cancer
January 2025
Medical Oncology Unit, Sant'Andrea Hospital, Rome, Italy. Electronic address:
Background: Medical cannabis (MC) has gained traction in oncology for managing cancer-related symptoms, but its integration faces challenges due to limited evidence, inconsistent guidelines, and varied legal frameworks.
Methods: The TASMAN study aimed to assess the knowledge, attitudes, and practices of oncologists and palliative care providers globally regarding MC use in cancer care. A survey of healthcare providers from diverse regions and income levels was conducted.
J Immunother Cancer
December 2024
Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden
Oxidative stress, that is, an unbalanced increase in reactive oxygen species (ROS), contributes to tumor-induced immune suppression and limits the efficacy of immunotherapy. Cancer cells have inherently increased ROS production, intracellularly through metabolic perturbations and extracellularly through activation of NADPH oxidases, which promotes cancer progression. Further increased ROS production or impaired antioxidant systems, induced, for example, by chemotherapy or radiotherapy, can preferentially kill cancer cells over healthy cells.
View Article and Find Full Text PDFClin Genitourin Cancer
November 2024
Division of Medical Oncology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Türkiye.
Introduction: KEYNOTE-361 evaluated first-line pembrolizumab with and without platinum-based chemotherapy versus chemotherapy alone in advanced or metastatic urothelial carcinoma. The primary end points of progression-free survival (PFS) or overall survival (OS) were not met. Exploratory analysis of efficacy by platinum agent (cisplatin or carboplatin) is reported.
View Article and Find Full Text PDFCurr Opin Oncol
January 2025
Department of Thoracic Surgery, Semmelweis University and National Institute of Oncology.
Radiol Case Rep
January 2025
Department of Radiology, National Institute of Oncology, UHC Ibn Sina, Mohamed V University, Rabat, Morocco.
Actinomycosis is a suppurative granulomatous infection caused by the Gram-positive bacillus Actinomyces israelii. It rarely affects the pelvis, but its incidence appears to be increasing, possibly due to the frequent use of intrauterine devices (IUDs). We report the case of a patient with an IUD in place for over 10 years who presented with pelvic pain, general health deterioration, and imaging findings suggesting a neoplastic origin.
View Article and Find Full Text PDFRadiol Case Rep
January 2025
Department of Radiology National Institute of Oncology, University Mohammed V of Rabat, Rabat, Morocco.
Plexiform neurofibroma is characterized by diffuse intraneural neoplastic overgrowth involving a long nerve segment, with tortuous expansion of its branches. It is a hallmark of Neurofibromatosis Type 1 (NF1). We report the case of a 36-year-old man with a known diagnosis of NF1, who was admitted for chronic posterior cervical pain and cervicobrachial neuralgia.
View Article and Find Full Text PDFClin Transl Oncol
November 2024
Department of Radiation Oncology, Catalan Institute of Oncology, Barcelona, Spain.
Physiol Int
November 2024
2Centre of Radiotherapy, National Tumor Biology Laboratory, National Institute of Oncology, Budapest, Hungary.
Kurume Med J
November 2024
Department of Oral Radiology, Osaka Dental University.
Background: The present study investigated the acute mucosal reaction (AMR) after high-dose-rate interstitial brachytherapy at 54 Gy/9 fractions (HDR54) as monotherapy administered twice a day for tongue cancer in 13 patients, and attempted to validate HDR54 by comparing the AMR with that of our previously reported HDR at 60 Gy/10 fractions (HDR60), and low-dose-rate interstitial brachytherapy at approximately 70 Gy (LDR70).
Methods: The European Organization for Research on Treatment of Cancer/ Radiation Therapy Oncology Group scoring system with modifications (score: 1-4.5) was used to evaluate AMR.
Cureus
October 2024
Pulmonology, Cheikh Khalifa International University Hospital, Mohammed VI University of Sciences and Health (UM6SS), Casablanca, MAR.
Catamenial hemothorax is a rare manifestation of thoracic endometriosis, characterized by blood in the pleural cavity associated with menstrual cycles. We present the case of a 42-year-old woman with recurrent right-sided chest pain and dyspnea coinciding with menstruation. Imaging revealed a large pleural effusion and hemothorax.
View Article and Find Full Text PDFMedicina (Kaunas)
November 2024
Chair of Surgery of the Faculty of Medicine and Health Sciences, Andrzej Frycz Modrzewski University, 30-705 Krakow, Poland.
Clin Transl Radiat Oncol
January 2025
Sana Kliniken Offenbach, Dep. Of Radiotherapy, Offenbach, Germany.
A survey regarding utilisation of brachytherapy was distributed to European brachytherapy professionals. Eighty replies from 26 countries were received, two of which were outside Europe. The replies showed that brachytherapy is still widely used.
View Article and Find Full Text PDFVirchows Arch
December 2024
Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
J Surg Oncol
October 2024
Department of Surgical Oncology, National Institute of Oncology, University Mohammed V in Rabat, Rabat, Morocco.
Crit Rev Oncol Hematol
January 2025
Department of Molecular Genetics, The National Tumor Biology Laboratory, National Institute of Oncology, Comprehensive Cancer Center, Ráth György út 7-9, Budapest H-1122, Hungary; Hereditary Tumours Research Group, Eötvös Loránd Research Network, Nagyvárad tér 4, Budapest H-1089, Hungary.
J Surg Oncol
November 2024
Department of Radiation Oncology, Catalan Institute of Oncology, Barcelona, Spain.